Home

At the heart of successful Pathology Labs

Masthead Alt Text

.

Masthead Alt Text

About Epredia

85 Years of Improving Lives through Enhancing Precision Diagnostics

Your expertise, our shared mission. Take a closer look at the trusted tools that form the foundation for excellence in cancer diagnostics.

Case Study Alt Text

News

Epredia Receives U.S. FDA 510(K) Clearance for the E1000 Dx™ Digital Pathology Solution

Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), today announced U.S. Food and Drug Administration (FDA) 510(K) clearance for its E1000 Dx Digital Pathology Solution (E1000 Dx). Read More